Literature DB >> 22813478

Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation.

Janice M Davis1, Ning Zhang, Robert W Payne, Brian M Murphy, Ahmad M Abdul-Fattah, James E Matsuura, Alan C Herman, Mark Cornell Manning.   

Abstract

Eight lyophilized formulations of a IgG1 monoclonal antibody (MAb) were prepared containing increasing levels of sucrose. In addition, three of the formulations had sorbitol added at a level of 5% w/w relative to sucrose. The samples were stored for up to 4 weeks at 40°C, which is well below the Tg. Upon reconstitution, the levels of subvisible particles were measured using microflow imaging (MFI). The formulation containing no sucrose contained exceedingly high levels of subvisible particles, accounting for as much as 25% of the weight of the protein. Addition of sucrose markedly decreased the number of subvisible particles, with the maximal sucrose:protein weight ratio being 2:1 (the highest level tested). Addition of sorbitol further decreased subvisible particle levels, even for formulations where the sucrose:protein ratio was relatively high. This suggests that even small amounts of a plasticizer like sorbitol can improve the storage stability of a lyophilized antibody formulation, probably by dampening β-relaxations within the amorphous glass.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22813478     DOI: 10.3109/10837450.2012.705295

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  3 in total

1.  Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.

Authors:  Srivalli Telikepalli; Ozan S Kumru; Jae Hyun Kim; Sangeeta B Joshi; Kristin B O'Berry; Angela W Blake-Haskins; Melissa D Perkins; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-12-17       Impact factor: 3.534

2.  Denaturation and Aggregation of Interferon-τ in Aqueous Solution.

Authors:  Ryan R Manning; Glenn A Wilson; Ryan E Holcomb; Nathaniel J Zbacnik; Auria A Tellechea; Chelsey L Gilley-Dunn; Ryan J Krammes; Nathan S Krammes; Gabriel J Evans; Charles S Henry; Mark Cornell Manning; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2018-05-09       Impact factor: 4.200

3.  Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase.

Authors:  Alexander M Faschinger; Nicole Sessler
Journal:  Adv Ther       Date:  2019-05-28       Impact factor: 3.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.